According to Market Research Future (MRFR), the Global Circulating Tumor Cell (CTC) Market is expected to acquire a valuation of USD 28,399.2 million by 2024, influenced by multiple positive factors. Additionally, it has been assessed to grow substantially at a CAGR of 20.32% over the forecast period of 2018-2023.
Circulating Tumor Cells are operated in cancer diagnostics and management, as a biomarker for the early detection of cancer, since they act as an indicator of treatment response and are beneficial in predicting results and projection in cancer management.
Get Free Sample @ https://www.marketresearchfuture.com/sample_request/1362
The growing prevalence of oncology diseases has increased the demand for CTC and consequently lead to the notable growth of the global circulatory tumor cells market. Additionally, the increasing need for the treatment of various chronic diseases has attracted significant investments by the biotechnology and pharmaceutical sector on research and development activities to develop advanced therapies for cancer and other chronic ailments. This is expected to contribute substantially to the growth of the global circulating tumor cells market.
CTC tests are expensive since they combine multiple enrichment and detection steps, which involve various assays, instruments, systems, and test kits. This may hamper the growth of the market over the forecast period. Additionally, unmet medical needs in developing regions and a critical lack of appropriate medical facilities in weak economies pose a challenge to the growth of the market.
Nevertheless, developing economies offer a high potential for growth opportunities for the global CTC market. Market players are shifting their focus to explore the market in such regions, to enhance the healthcare sectors, and consequently contribute to the growth of the CTC market.
Circulating Tumor Cell Market – Key Players
The prominent players in the Global Circulating Tumor Cell Market are
- Hoffmann-La Roche Ltd
- Fluxion Biosciences, Inc.
- Greiner Bio-One International GmbH
- Ikonisys Inc.
- Menarini Silicon Biosystems
- Miltenyi Biotec
- NanoString Technologies, Inc.
- QIAGEN Hannover (QIAGEN)
- STEMCELL Technologies
- SRI International
- Thermo Fisher Scientific
Circulating Tumor Cell Market – Segmental Analysis
The Global Circulating Tumor Cell Market has been segmented based on application, technology, and end-user.
Based on application, the CTC market has been segmented into clinical, drug development, and research. The clinical segment has been sub-segmented into clinical prognostic, diagnosis and management of tumor malignancies, and drug decision. The clinical segment is expected to reach a valuation of USD 18,225.8 million by the end of the forecast period. The clinic segment is followed by the drug development segment owing to the shifting focus of pharmaceutical and biotech companies towards CTC for drug development.
Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/1362
Based on technology, the market for circulating tumor cell has been segmented into combined enrichment and separation of CTC (CTC analysis), CTC detection, and CTC enrichment. CTC enrichment is accounted for the largest market share, owing to its efficiency to reduce the time required for the isolation of rare CTCs.
Based on end-user, the CTC market has been segmented into diagnostic centers, hospitals & clinics, and research & academic institute. The hospitals and clinics segment accounts for the leading market share and is estimated to reach a valuation of USD 9,184.9 million by 2024. This is attributed to the constant demand for diagnosis and treatment of cancer, consequently driving the segment growth. The hospitals and clinics end-user segment are anticipated to grow at a CAGR of 20.92% over the forecast period.
Circulating Tumor Cell Market – Regional Analysis
Based on the region, the market has been segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas account for the largest regional market for circulating tumor cell, owing to the high prevalence of cancer in this region. The region is expected to maintain the leading market share over the forecast period, growing at a CAGR of 20.56% and acquiring a valuation of USD 13,011.5 million. The early adoption of advanced technologies, and the well-established healthcare sector in the region, especially in the U.S., are primary factors contributing to market growth.
Europe is the second largest region in the global CTC market, owing to the increasing expenditure by the government towards research and development activities to expand the diagnosis and treatment facilities offered to consumers, especially for cancer affected patients.
The Asia Pacific is the fastest growing region of the Circulating Tumor Cell Market and is expected to grow over the forecast period at a CAGR of 20.84%. The high growth rate is attributable to the emerging economies such as India and China, which serve as opportunities for market growth, owing to the rising prevalence of cancer, and technological advancements.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
+1 646 845 9312